Our research in pathophysiological particularly focuses on type 2 diabetes and the mechanisms associated with development of type 2 diabetes. Ultimately this should provide new targets for prevention, detection, and treatment of type 2 diabetes.
At present, targeted drug treatment of insulin resistance is practically non-existent. Improved understanding of pathophysiological mechanisms and identification of new points of attack for treatment of insulin resistance are therefore crucial to the development of new principles of prevention and treatment of type 2 diabetes and cardiovascular disease.
The clinical research in pathophysiology at Steno Diabetes Center Odense encompasses ‘state-of-the-art’ studies of glucose and lipid metabolism, as well as beta cell function in vivo in patients with type 2 diabetes and people at high risk of developing type 2 diabetes. The molecular research in pathophysiology provides facilities for molecular characterization of human biopsy material as well as cell culturing and manipulations to provide mechanistic causes of the phenotypes observed in the human biopsies. The combination of clinical and molecular research provides a unique setting to perform translational characterization of both the clinical and molecular mechanisms underlying insulin resistance and type 2 diabetes in humans.
Collaboration
Pathophysiological research will be conducted in close collaboration between researchers at OUH and the Region’s other hospitals, the Department of Clinical Research at SDU, and a number of the University’s other research environments.
Program Manager
Professor Kurt Højlund
